POTS

For health professionals General practice

A young woman, a racing heart on standing, years of "it's anxiety" and an average of five doctors before anyone measures her pulse lying and standing. Postural orthostatic tachycardia syndrome is diagnosed with a watch and a bed, managed mostly in general practice, and surrounded by more hype than trials. Criteria, a stand test you can run on Monday, and an honest read of the evidence.

At a glance

For patients, in one line: POTS makes your heart race and you feel unwell when you stand, it's diagnosed with a simple lying-and-standing test, and most people improve with a steady plan. Read the plain-English POTS page.

Definition

• What it is: a chronic syndrome of orthostatic intolerance whose cardinal feature is excessive, sustained tachycardia on standing, without a fall in blood pressure. Symptoms ease on lying down.
• Heart rate: rise of ≥30 bpm within 10 minutes of standing or head-up tilt; ≥40 bpm at ages 12–19. CMAJ's summary of the Canadian criteria asks for it on at least 2 readings at least 1 minute apart.
• Blood pressure: no sustained orthostatic hypotension (fall ≥20 systolic or ≥10 diastolic). Transient initial orthostatic hypotension in the first seconds doesn't exclude POTS.
• Symptoms: lightheadedness, palpitations, tremulousness, weakness, blurred vision, exercise intolerance and fatigue, present ≥3 months.
• Exclusion: no other cause, such as dehydration, anaemia, hyperthyroidism, medicines or prolonged bed rest.
• ESC 2018 wording: a rise >30 bpm or to >120 bpm within 10 minutes. Some Australian GP guidance repeats the >120 bpm option; HRS and CCS use the rise alone.
• New in 2026: an international Delphi consensus (Sivakoti et al, Am J Med; 31 statements, 7 countries) calls POTS one phenotype of dysautonomia and proposes "non-POTS dysautonomia" for disabling orthostatic intolerance that misses the heart rate threshold. It is a research and care framework, not a replacement for the criteria.

What it isn't

• Orthostatic hypotension: a sustained BP fall within 3 minutes. If present, it isn't POTS.
• Inappropriate sinus tachycardia: resting rate ≥100 bpm or 24-hour mean >90 bpm, not mainly positional.
• Vasovagal syncope: usually normal orthostatic vitals between episodes. It can coexist with POTS.
• SVT: sudden onset and offset, not positional, may stop with a Valsalva manoeuvre.
• Just a fast pulse on standing: teenagers and deconditioned people can hit the number without the syndrome. Symptoms, chronicity and exclusions all count.

History

• 1871, Jacob Mendes Da Costa: described "irritable heart" in about 300 American Civil War soldiers, later called soldier's heart or effort syndrome. Some of what he saw overlaps with POTS; it was not the same diagnosis.
• 1993: POTS was characterised and named as a distinct syndrome (Schondorf and Low at the Mayo Clinic, as credited by PoTS UK).
• 2008, Joyner and Masuki: the Streeten Lecture argued deconditioning is central, comparing POTS with bed rest and spaceflight.
• 2010, Fu and Levine (Dallas): small hearts and low blood volume, both improved by training. The Dallas programme became the template for the CHOP protocol.
• 2015: Heart Rhythm Society expert consensus on POTS, inappropriate sinus tachycardia and vasovagal syncope.
• 2019–2021: NIH expert meeting (published 2021) and the Canadian Cardiovascular Society position statement (2020).
• 2020s: long COVID brought a surge of new cases and the first larger RCTs, including RECOVER-AUTONOMIC.

Pathophysiology

Mostly hypotheses. Phenotypes overlap, and none has a validated test that changes treatment for most patients.

• Common pathway: on standing, blood pools in the legs and splanchnic bed, stroke volume falls, and the heart rate rises to compensate. In POTS that compensation is excessive and symptomatic.
• Neuropathic (hypothesis): partial sympathetic denervation of the legs means less vasoconstriction and more pooling. The HRS consensus cites peripheral denervation in up to 50% of patients.
• Hypovolaemic: low plasma volume with inappropriately low renin and aldosterone, reported in about 70% (HRS). Fu 2010: blood volume 60 vs 71 mL/kg in controls.
• Hyperadrenergic: standing noradrenaline ≥600 pg/mL in some, often with a BP rise on standing, tremor and anxiety-like symptoms. Whether it's a cause or a consequence is unsettled.
• Deconditioning debate: Fu 2010 found lower left ventricular mass (1.26 vs 1.45 g/kg; "a small heart coupled with reduced blood volume"), and 3 months of training raised it by about 12%. Joyner and Masuki argue deconditioning drives much of the picture. Against a pure deconditioning model: onset in fit people after infection, and many trained patients still meet criteria.
• Autoimmune (hypothesis): post-viral onset and autoimmune comorbidity are suggestive. But Hall 2022 (Circulation, 116 patients, 81 controls) found no difference in G protein-coupled receptor autoantibodies by standard ELISA: 98.3% of patients and 100% of controls were "positive" for α1 antibodies. IVIG failed its RCT (see below).
• Post-COVID: cardiovascular autonomic dysfunction may affect about a third of highly symptomatic people with long COVID (Fedorowski, Nat Rev Cardiol 2024). Mechanisms remain speculative.

Epidemiology

Global

• Prevalence: about 0.2% (HRS 2015); estimates range from 0.1% to 1% (CMAJ 2022). No robust population survey exists.
• Sex and age: ≥75% women, most often 15–25 at onset (HRS); typically girls and women from puberty through early adulthood. PoTS UK cites ages 15–50.
• Comorbidities (CMAJ 2022): fatigue in >90%, at least half meet ME/CFS criteria, migraine about 40%, hypermobile EDS or hypermobility spectrum disorder 20–30%, autoimmune disease about 15%.
• Psychiatric labels: 77% reported a psychiatric diagnosis before POTS was recognised, falling to 37% after (CMAJ, citing survey data).

Australia

• Registry (Seeley et al, MJA 2025): 500 people aged 16+ seen at an Adelaide specialist clinic, 2021–24. 86.8% women, mean age 31; median onset 22 in adults and 14 in adolescents.
• Triggers: infection 39.4% (SARS-CoV-2 32.6%), none identified 35.8%, trauma or concussion 6.8%, vaccination 5.8%, surgery 3.4%.
• Delay: mean 6.7 years; over 10 years for a quarter. Longer for women (7.0 vs 3.8 years). Delay fell to 1.6 years for those diagnosed from 2019, vs 12.9 before.
• Before diagnosis: 5.2 doctors seen on average, anxiety blamed in 64.6%, emergency presentations in 54.5%.
• Impact: 22% unemployed and 18.2% in full-time work; EQ-5D utility 0.591. The cohort was 96.6% white, so it says little about First Nations or migrant Australians.
• Services: an Australian-led 2026 state-of-the-art review (Lau et al, Heart Lung Circ) describes a "dearth" of specialists and recommends a GP-anchored multidisciplinary team.

Triggers and associations

Association is not causation. Each line says how strong the evidence is.

• Viral illness, including COVID-19 (moderate, observational): Kwan 2022 (Cedars-Sinai records): POTS-associated diagnoses rose after infection (OR 1.52) and, less, after vaccination (OR 1.33). The outcome lumped POTS with fatigue, EDS and mast cell codes. In a Karolinska cohort of 467 people on long-term sick leave with long COVID, 31% met POTS criteria: a highly selected group.
• Hypermobility and hEDS (suggestive, mostly clinic series): Miller 2020: 31% of 91 POTS patients met 2017 hEDS criteria, and a further 24% had generalised hypermobility. Selection bias is likely; there were no population controls.
• Mast cell activation syndrome (weak): a 2020 review of the claimed hEDS–POTS–MCAS triad found only a handful of original studies, inconsistent MCAS criteria and no shown common mechanism. Look for MCAS when there are objective features, not by default.
• Other reported triggers: surgery, trauma, concussion and pregnancy (registry and clinic data only).
• Prevention: we found no evidence on preventing POTS. Avoiding prolonged bed rest during illness is plausible, given the deconditioning data, but untested.

Assessment in general practice

History and examination

• Ask about: onset and trigger, which postures and situations worsen it (heat, showers, meals, standing in queues), fluid and salt intake, diet and weight change, exercise, menstrual pattern, sleep, medicines including over-the-counter and recreational drugs, and family history of sudden cardiac death.
• Measure function: school, work and days in bed. These guide treatment better than the heart rate.
• Examine: murmurs, hydration, thyroid, hypermobility (Beighton score), and dependent acrocyanosis on standing (reported in about half).

The active stand test, step by step

1. Prepare. Morning testing is more sensitive. Note rate-slowing and vasoactive medicines, caffeine and recent fluid intake. Have a chair and a second person nearby.
2. Lie supine for 5–10 minutes. Record heart rate and blood pressure at the end.
3. Stand up unaided, feet slightly apart, without leaning, and minimise talking and fidgeting.
4. Record HR and BP at 1, 3, 5, 8 and 10 minutes (the CMAJ protocol). PoTS UK suggests every 2 minutes for 10 minutes; either is fine.
5. Record symptoms and signs at each point: lightheadedness, palpitations, colour change in the legs, tremor.
6. Stop and lie the patient down if they become presyncopal. Record the values at that point.
7. Interpret. Sustained rise ≥30 bpm (≥40 at 12–19) on at least 2 readings; no sustained fall ≥20/10 mmHg within 3 minutes. A BP rise on standing points towards a hyperadrenergic picture.
8. If negative but the story is strong, repeat on another morning, off caffeine, before referring for a tilt test.

What to exclude

• Hypovolaemia: poor intake, vomiting or diarrhoea, diuretics, restrictive eating or an eating disorder.
• Anaemia and iron deficiency.
• Endocrine: hyperthyroidism, adrenal insufficiency (Addison's), phaeochromocytoma, carcinoid.
• Medicines and substances: diuretics, antihypertensives and vasodilators, SNRIs and tricyclics, stimulants, β-agonists, caffeine, alcohol, cannabis and other recreational drugs.
• Cardiac: SVT, inappropriate sinus tachycardia, structural heart disease.
• Other: prolonged bed rest, pregnancy, panic disorder (it can coexist; it doesn't explain a reproducible postural tachycardia).

Basic investigations

• Most people: FBC, ferritin or iron studies, electrolytes and renal function, TSH, morning cortisol, 12-lead ECG. Add LFTs and β-hCG where relevant (Metro North adds both).
• Selected: 24-hour Holter (for IST or a possible arrhythmia), echocardiogram if the examination or ECG is abnormal, plasma metanephrines if hypertensive or episodic, coeliac serology with GI symptoms.
• Specialist: tilt table, autonomic reflex testing, supine and standing catecholamines, blood volume. Optional, not routine.
• Don't order: commercial "POTS autoantibody" panels. They don't distinguish patients from controls (Hall 2022).

Red flags: refer urgently or rethink the diagnosis

• Syncope during exertion, or while supine.
• Chest pain, or syncope preceded by palpitations.
• Family history of sudden cardiac death or inherited cardiac disease at a young age.
• Abnormal ECG: pre-excitation, long or short QT, Brugada pattern, heart block, or a hypertrophy pattern.
• A new murmur, or signs of heart failure.
• Weight loss, significant orthostatic hypotension, or features of a systemic disease.

When to refer routinely

• When the diagnosis is uncertain, symptoms are severe, or first-line care hasn't helped after a fair trial (Metro North GP guidance).
• Cardiology, neurology or an autonomic clinic, depending on local access. Waits can be long, so start non-drug care while waiting: delay may worsen outcomes.
• Include stand-test numbers, investigations, medicines tried and functional impact in the referral.

Current treatment

First: education and non-drug care

• Explain and validate: it's a real physiological disorder. Expect gradual improvement over months, not days.
• Fluids: 2–3 L a day (HRS); CCS suggests 3 L. Two glasses before getting up helps mornings.
• Salt, where safe: HRS suggests 10–12 g of salt a day; PoTS UK suggests an extra 6 g. Garland 2021 (n=14, crossover, 6 days): a very high-sodium diet raised plasma volume and lowered upright heart rate. Avoid or seek advice with hypertension, kidney disease, heart failure or pregnancy-related hypertension.
• Compression: waist-high or abdominal compression, not knee-highs. Bourne 2021 (n=30, crossover on tilt): full abdominal and leg compression lowered heart rate from 109 to 92 bpm and improved symptoms.
• Exercise, recumbent first: rowing, recumbent bike or swimming, building to upright over months. Fu 2010: after 3 months, 10 of 19 completers no longer met criteria. George 2016 (international registry): 71% of 103 completers no longer met criteria, but 251 enrolled and there was no control group. Patients often feel worse for the first month or so.
• The CHOP modified Dallas programme: 8 monthly calendars. Months 1–3 horizontal only; an upright bike in month 4; walking and an elliptical from month 5. With strength training. An exercise physiologist or physio can run it, with Medicare rebates under a GP chronic condition plan.
• Caution: in long COVID or ME/CFS with marked post-exertional malaise, pace more slowly (PoTS UK).
• Counter-manoeuvres: cross the legs, tense the buttocks and thighs, fold the arms, go on tiptoe, or sit or lie down at the first symptoms.
• Daily triggers: heat, hot showers (sit to wash), large carbohydrate meals and alcohol. Keep a regular sleep routine.
• Stop or review medicines that worsen tachycardia or BP: diuretics, antihypertensives, SNRIs.

Then: medicines (all off-label for POTS)

No medicine is TGA-registered or PBS-listed for POTS. No large multicentre RCT supports any of them. Start one at a time, low, and stop if there's no benefit. Use specialist input for combinations or pregnancy.

• Propranolol, low dose: the best-studied option and a strong recommendation from CCS. Raj 2009 (crossover): 20 mg lowered standing heart rate and improved symptoms vs placebo, and 80 mg was no better for symptoms. "Less is more." Cautions: asthma, fatigue, hypotension, depression.
• Ivabradine: slows the sinus rate without lowering BP. Taub 2021 (n=22, 1-month crossover, hyperadrenergic POTS): standing heart rate about 77 bpm and better quality of life. RECOVER-AUTONOMIC (2026, n=181, long COVID POTS, 3 months): heart rate fell more than with placebo, but symptoms didn't improve (P=0.63). Avoid in pregnancy; it can cause visual flashes (phosphenes). Usually a private script for POTS.
• Fludrocortisone: expands volume. Its evidence is stronger for vasovagal syncope than POTS. Watch potassium, BP and oedema.
• Midodrine: an α1-agonist for patients with lower BP or prominent pooling. Watch for supine hypertension (avoid bedtime doses) and scalp tingling. In Australia it is registered only for severe symptomatic orthostatic hypotension due to autonomic dysfunction. The Australian POTS Foundation has asked for POTS to be added (2024).
• Pyridostigmine: an acute crossover study (2005) showed lower standing heart rate. GI effects are common: useful with constipation, poor with diarrhoea.
• Hyperadrenergic picture: clonidine or methyldopa (narrow window, so start low).
• Occasionally: desmopressin (monitor sodium); SSRIs or SNRIs for some, though SNRIs can raise heart rate.
• IV saline: rescue for a severe flare only. Regular infusions risk line infection and clots.
• Not recommended: sinus node ablation or modification (HRS and CCS: unproven and harmful).

A lower heart rate is a number. A patient who can stand in a supermarket queue is an outcome. Trials, and clinicians, should count the second.

Emerging treatments and trials

• RECOVER-AUTONOMIC (NIH platform, phase 2): ivabradine vs placebo, crossed with coordinated non-drug care vs usual care. The primary symptom outcome (OHQ) was negative for ivabradine. The interaction with coordinated care was significant (P=0.004), favouring ivabradine plus coordinated care. Presented at ACC.26; the full paper was not yet published when we checked. We found no reported results for the IVIG arm.
• IVIG (iSTAND, 2024): 30 patients randomised to IVIG or albumin. Response 46.7% vs 38.5%, not significant. Both groups improved, possibly from volume expansion. Small, but the best test yet of the autoimmune theory.
• Under study, limited evidence: droxidopa, very low-dose naltrexone, transcutaneous vagal nerve stimulation, continuous oral contraceptive for cyclical flares, and hyperbaric oxygen (listed as novel in Australian GP guidance). None is ready for routine use.
• Coordinated care itself: RECOVER-AUTONOMIC's signal suggests the structured non-drug package may matter more than the pill. Hypothesis, pending the full paper.

Special groups

Adolescents

• Criteria: a ≥40 bpm rise at ages 12–19, because healthy teenagers have a larger orthostatic heart rate rise.
• Outcome (Bhatia 2016, Mayo, mean 5.4 years): 19% resolved, 51% persistent but improved, 16% intermittent (86% combined). Only 34% responded, so selection bias is possible.
• School: a written plan for water bottles, salty snacks, toilet access, rest breaks, lifts, and modified PE rather than exemption.

Pregnancy

• Course: stable or improved in about 60–68%, worse in 30–40%. Often worse in the first trimester and better in the second (Morgan 2022 review; small studies).
• Obstetric outcomes: complications don't appear clearly higher, though hyperemesis may be commoner. No RCTs or consensus guidelines exist.
• Plan: review medicines before conception. Ivabradine should be avoided. Use the fewest medicines at the lowest effective dose, with obstetric and specialist input. Early epidural and fluids around delivery are suggested.

Prognosis and quality of life

• Generally: chronic, but most improve over time (HRS). Adult natural history is poorly studied, and many adults don't reach lasting remission (CMAJ).
• Adolescents: better; see Bhatia 2016.
• A longer wait means a worse outcome: a longer symptom duration before treatment predicts a worse outcome in young people (CMAJ). Another reason to measure early.
• Burden: Australian quality-of-life scores are similar to many serious chronic diseases (EQ-5D 0.591), and the burden is similar in adolescents and adults.

Talking to patients

• Name it: "Your heart rate is doing its job too enthusiastically because blood pools when you stand. It's real, it's measurable, and it usually improves."
• Set the timescale: months. Exercise may feel worse before it feels better.
• Share the numbers: give them their stand-test results. Home lying-and-standing readings are useful; daily obsessive monitoring isn't.
• Be honest about the drugs: they help some people, none is approved for POTS, and none replaces the basics.
• Protect them from the market: antibody panels, routine drips and expensive supplements. Ask what they've been sold.
• Mental health: screen and treat anxiety or depression when present, without making it the explanation.

Myths

• "It's just anxiety." Anxiety can coexist, but it doesn't produce a reproducible ≥30 bpm postural rise without hypotension. In Australia, 64.6% were told it was anxiety first.
• "Rest until it settles." Bed rest deconditions, and deconditioning worsens orthostatic tolerance.
• "You need a tilt table to diagnose it." An active stand is enough in most cases; tilt is optional.
• "The antibody test proves it's autoimmune." Controls test positive too.
• "IVIG or weekly drips are the cure." IVIG failed its RCT; regular drips carry line risks.
• "POTS, hEDS and MCAS always come as a set." They overlap in clinics; the triad isn't established.
• "Get the heart rate down and they'll be fine." RECOVER-AUTONOMIC lowered heart rate without improving symptoms.
• "It's a teenage girl thing that's outgrown." Many improve, but onset spans to middle age and men get it too, often diagnosed faster.

Gaps and open questions

Labelled hypotheses, not recommendations.

• One disease or several? Hypothesis: phenotype-guided treatment (volume vs vasoconstrictor vs rate control) beats trial and error. We found no RCT testing that.
• Outcomes: most trials report heart rate after one dose or one month. Long-term function, school and work are rarely measured.
• Autoimmunity: hypothesis still alive, but standard antibody assays and IVIG have both disappointed. Better assays or better-selected patients are needed.
• Long COVID: is post-COVID POTS the same disease? Hypothesis: it is more often coupled with post-exertional malaise, which changes how hard to push exercise.
• Sex difference: why ≥75% women? Hormonal cycling, smaller blood volume and heart size, and immune differences are all proposed; none is proven.
• Equity: the Australian registry was 96.6% white and specialist-referred. We found no data on POTS in First Nations, rural or culturally diverse Australians.
• Access: no PBS-listed option, few autonomic clinics, and allied health costs. Hypothesis: GP-led structured care with an exercise physiologist closes much of the gap. Worth trialling in Australia.

What to do on Monday

• Suspect it: young, orthostatic symptoms ≥3 months, better lying down, "anxiety" in the notes. Especially after a virus.
• Measure it: a 10-minute active stand in the room: 5–10 minutes lying, then HR and BP at 1, 3, 5, 8 and 10 minutes standing.
• Screen sensibly: FBC, ferritin, UEC, TSH, morning cortisol, ECG; more only if indicated.
• Look for red flags: exertional syncope, chest pain, a family history of sudden death, an abnormal ECG. Refer those promptly.
• Start the basics: fluids 2–3 L, salt if safe, waist-high compression, a recumbent exercise plan with an exercise physiologist, counter-manoeuvres, and a medicine review.
• Review in 4–8 weeks: function first. Consider low-dose propranolol if heart rate symptoms dominate and there's no contraindication.
• Refer if the diagnosis is uncertain, symptoms are severe, or there's no progress after a fair trial. Keep managing while they wait.
• Hand over: the patient POTS page and a school or work letter if needed.

Weird trivia

• Grinch syndrome: Fu and Levine's 2010 paper proposed the nickname, after the Dr Seuss character whose heart was "two sizes too small".
• Astronauts: spaceflight and bed rest reproduce orthostatic tachycardia in healthy people. That's part of the deconditioning argument.
• Soldier's heart: Da Costa's 1871 description came from Civil War soldiers, not young women.
• The number 30: the ≥30 bpm threshold is a consensus cut-off. ESC 2018 also accepts a rise to over 120 bpm.
• Salt as a prescription: HRS suggests 10–12 g a day, more than double the WHO limit of under 5 g. Rarely is "eat more salt" written by a doctor.

Guidelines

• Sheldon RS et al. 2015 HRS expert consensus statement on POTS, IST and vasovagal syncope. Heart Rhythm 2015
• EP Lab Digest: review of the 2015 HRS consensus
• Raj SR et al. Canadian Cardiovascular Society position statement on POTS. Can J Cardiol 2020
• Raj SR, Fedorowski A, Sheldon RS. Diagnosis and management of POTS. CMAJ 2022
• Vernino S et al. POTS: state of the science, 2019 NIH expert consensus meeting, part 1. Auton Neurosci 2021
• Brignole M et al. 2018 ESC guidelines for the diagnosis and management of syncope (PDF)
• Sivakoti K et al. POTS and dysautonomia: international multidisciplinary expert consensus. Am J Med 2026
• Lau DH et al. POTS: a state-of-the-art review. Heart Lung Circ 2026
• Metro North Health (Qld): POTS management for GPs (PDF)
• PoTS UK: PoTS on a page, GP guide (PDF)

Key trials and studies

• Raj 2009 (Circulation): low-dose propranolol beat placebo and 80 mg for symptoms.
• Fu 2010 (JACC): small heart, low blood volume; training reversed both.
• George 2016 (Heart Rhythm): 71% of exercise completers no longer met criteria; uncontrolled.
• Bhatia 2016 (J Pediatr): 86% of adolescents resolved or improved at about 5 years.
• Miller 2020 (Auton Neurosci): 31% hEDS in a POTS clinic sample.
• Bourne 2021 (JACC): abdominal and leg compression cut tilt heart rate by about 17 bpm.
• Garland 2021 (JACC): high sodium raised plasma volume and lowered upright heart rate.
• Taub 2021 (JACC): ivabradine in hyperadrenergic POTS, n=22.
• Hall 2022 (Circulation): receptor autoantibodies no different from controls.
• Kwan 2022 (Nat Cardiovasc Res): POTS-associated diagnoses after infection and, less, vaccination.
• iSTAND 2024 (Clin Auton Res): IVIG no better than albumin.
• Seeley 2025 (MJA): Australian registry, 6.7-year diagnostic delay.
• RECOVER-AUTONOMIC 2026 (ACC.26): ivabradine lowered heart rate, not symptoms.

Sources

• Seeley M-C et al. Symptom burden, quality of life and diagnostic journey of people with POTS, Australia, 2021–24. Med J Aust 2025
• Australian POTS Foundation: midodrine repurposing nomination, April 2024 (PDF)
• Fedorowski A et al. Cardiovascular autonomic dysfunction in post-COVID-19 syndrome. Nat Rev Cardiol 2024
• TCTMD: Kwan AC et al. POTS diagnoses after COVID-19 vaccination and infection. Nat Cardiovasc Res 2022
• CIDRAP: Karolinska long COVID cohort, 31% with POTS. Circ Arrhythm Electrophysiol
• Miller AJ et al. Prevalence of hEDS in POTS. Auton Neurosci 2020
• Kucharik AH, Chang C. The relationship between hEDS, POTS and MCAS. Clin Rev Allergy Immunol 2020
• Fu Q et al. Cardiac origins of POTS. J Am Coll Cardiol 2010
• Joyner MJ, Masuki S. POTS versus deconditioning: the same or different? Clin Auton Res 2008
• Hall J et al. G protein-coupled receptor autoantibodies in POTS. Circulation 2022
• Raj SR et al. Propranolol in POTS: less is more. Circulation 2009
• Taub PR et al. Randomised trial of ivabradine in hyperadrenergic POTS. J Am Coll Cardiol 2021
• Garland EM et al. High dietary sodium in POTS. J Am Coll Cardiol 2021
• Bourne KM et al. Compression garment reduces orthostatic tachycardia in POTS. J Am Coll Cardiol 2021
• George SA et al. International POTS registry exercise programme. Heart Rhythm 2016
• CHOP modified Dallas POTS exercise programme (PDF)
• Vernino S et al. IVIG for autoimmune POTS (iSTAND). Clin Auton Res 2024
• RECOVER: RECOVER-AUTONOMIC results at ACC 2026
• Pharmacy Times: RECOVER-AUTONOMIC ivabradine outcomes (ACC.26)
• RECOVER: RECOVER-AUTONOMIC design (IVIG, ivabradine, coordinated care)
• Bhatia R et al. Outcomes of adolescent-onset POTS. J Pediatr 2016
• Morgan K, Smith A, Blitshteyn S. POTS and pregnancy. Int J Womens Health 2022
• ACC: practical instructions for the 2018 ESC syncope guidelines
• Da Costa's syndrome (background)
• Healthdirect: POTS

Information only. All POTS medicines are off-label. Check product information, PBS status, contraindications and specialist advice before prescribing, and follow local referral pathways.

Reviewed 7 November 2026. General education for health professionals; not a substitute for local protocols or clinical judgement.

maladywise.com/deep-dives/pots/